Mailing Address
45 Rockefeller Plaza, 20th Floor, New York, NY 10111
212-268-1002
Washington DC Office
1101 14th Street NW, Suite 850, Washington, DC 20005
866-399-6262 (Toll Free) | 202-331-2292 (Fax)
Make an online donation today.
Mail your contributions to the address below:
Ovarian Cancer Research Alliance
Post Office Box 32141
New York, NY 10087-2141
Tax ID #13-3806788
We’re here for you! Our Patient Support team is available to take your calls Monday – Friday. Call 212-268-1002 and if no one is available when you call, someone will get back to you within 24 hours.
For all press inquiries, please contact:
Amanita Duga-Carroll
ADC Strategic Communications, Inc.
Audra Moran, President and CEO of Ovarian Cancer Research Alliance (OCRA), has been recognized as a Crain’s New York Business 2026 Notable Leader in Health Care. Crain’s annual recognition spotlights health care executives whose leadership, innovation, and community commitment set a high bar for the field. Honorees are selected based on demonstrated impact, both within … Continued
This article was updated in April 2026 to reflect NCCN’s release of the 2026 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2026 Patient Guidelines for Cervical Cancer and Uterine Cancer, and the 2025 Patient Guidelines for Ovarian. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful … Continued
On March 25, 2026, the U.S. Food and Drug Administration (FDA) approved Lifyorli (relacorilant), made by Corcept Therapeutics, in combination with Abraxane (nab-paclitaxel) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior lines of treatment, including prior Avastin (bevacizumab). The approval follows last month’s FDA … Continued
Get email updates about research news, action alerts, and ways to join the fight.
